What if you invested $1000 in INCY on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Incyte Corporation has delivered an average annual return of 26.3%. The stock peaked in 2013 with a massive +197.8% gain, while investors faced a downturn in 2008 (-62.0%). Overall, the stock finished in the green 13 times out of 20 years.
Avg Return
+26.3%
Win Rate
65%
13W - 7L
Best
+197.8%
2013
Worst
-62.0%
2008
Performance Consistency
About Incyte Corporation
Visit Website ↗Incyte Corporation is an American multinational biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in the areas of hematology, oncology, inflammation, and autoimmunity. The company aims to address unmet medical needs through innovative science.
Key Business Segments
Hematology & Oncology
Focuses on the development and commercialization of treatments for blood cancers and other oncological conditions.
Inflammation & Autoimmunity
Engages in research and development of therapies for inflammatory and autoimmune diseases.
Key Innovations
- ✓Discovery and development of several proprietary therapeutic products, such as Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (ruxolitinib cream), Iclusig (ponatinib), Zynyz (retifanlimab-dlwr), and Niktimvo (axatilimab-csfr), addressing various medical conditions.
- ✓Ongoing commitment to innovative scientific research to bring new treatments to patients with unmet medical needs.
Historical Milestones
Company founded, establishing its foundation in biopharmaceutical research.
Multiple therapeutic products commercialized and approved globally, contributing to patient care in hematology, oncology, and inflammation.